SOURCE: MERISTEM Therapeutics

November 15, 2007 10:33 ET

MERISTEM Therapeutics & SBH Sciences Announce Agreement for Joint Development of Animal-Free Recombinant Proteins

CLERMONT-FERRAND, FRANCE and CAMBRIDGE, MA--(Marketwire - November 15, 2007) - MERISTEM Therapeutics and SBH Sciences have entered an agreement to co-develop recombinant proteins produced in genetically engineered tobacco for research and development and diagnostic applications. The first proteins selected for development are human proteins from the growth factor and hormone families. Through the combined expertise of MERISTEM and SBH the companies will strive to provide a large variety of human proteins to Research and Development organizations. Meristem's experience and know-how in plant-based stable expression of proteins combined with SBH's customized purification technology will ensure speed up of production and superior quality of proteins. Proteins expressed in Meristem's system are free of pathogens transmissible to humans.

About MERISTEM Therapeutics

MERISTEM Therapeutics ("MERISTEM") of Clermont-Ferrand, France is a private, venture-capital backed Biotechnology Company that has developed advanced manufacturing capabilities for the production of recombinant proteins in plants. Meristem's transgenic plant technology competes with established methods of manufacturing biopharmaceuticals and is considered a cost-effective alternative for proteins difficult to express in other systems.

Expression technologies using non-food plants grown in a contained environment is the latest advancement for MERISTEM. This technology is being utilized for applications in both animal and human health. Key advantages are the safety of a confined and controlled environment without sacrificing the capability to scale-up production quickly and cost-effectively.

About SBH Sciences

SBH Sciences (Natick, MA.) provides cell culture based services to the Biotechnology and Pharmaceutical industry and academic researchers. In its tenth year of operation, SBH Sciences is making significant advances in proprietary cell culture technology, specifically in mammalian and insect cell culture, optimizing in-vitro diagnostic methods, as well as customizing the production and purification of proteins.

SBH Sciences excels in the development and validation of cell-based bioassays for biologically active cytokines and currently has the most comprehensive assay library worldwide. Assays consist of over 200 different cytokines, cytokine receptors and anti-cytokines, with assay endpoints including proliferation, neutralization, cytotoxicity, complement dependent cytotoxicity, agonistic and antagonistic activities. They specialize in cytokine and protein profiling as well as immunological based assays.

Contact Information

  • Contact:
    Kathleen Marker
    Manager Business Development
    MERISTEM® Therapeutics
    Tel 33 473 98 68 45
    Fax 33 473 98 68 19
    Email: Email Contact